News
-
ENA Respiratory announced that it has received a contract extension from the US Department of Defense (DoD), providing additional funds for continued development of INNA-051, a dry powder intranasal TLR2/6 agonist. In January 2023, ENA… Read more . . .
-
Avalyn Pharma has announced the initiation of the Phase 2b MIST study of AP01 pirfenidone inhalation solution in patients with progressive pulmonary fibrosis (PPF). In March 2023, the company announced that a Phase 1b trial of nebulized… Read more . . .
-
According to Arcturus Therapeutics, the FDA has cleared an investigational new drug application allowing the company to proceed with a Phase 2 MAD trial of its ARCT-032 inhaled mRNA therapy in people with cystic fibrosis.… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) announced that marketing specialist Mats Håkansson will take over the CEO role from Lars Asking. According to the announcement, Asking, who had served as the CEO of MVIC since 2017,… Read more . . .
-
ENA Respiratory announced that it has completed a Phase 1a study and has initiated a Phase 1b study of its INNA-051 TLR2/6 agonist pan-viral nasal powder in people aged 60 and older. Earlier this year,… Read more . . .
-
ARS Pharmaceuticals announced that the European Commission has approved the company’s EURneffy adrenaline nasal spray for the treatment of anaphylaxis. The approval comes soon after the FDA’s approval of the US version, Neffy epinephrine nasal spray. The EMA’s Committee… Read more . . .
-
Soon after the FDA granted temporary approval to Liquidia’s sNDA for Yutrepia treprostinil DPI, the company announced that it has filed a lawsuit challenging the FDA’s grant of 3-year new clinical investigation exclusivity to United… Read more . . .
-
Pharma Nordic has expanded its distribution agreement with Altamira Medica for Bentrio nasal spray, adding Sweden and Denmark, the companies announced. Bentrio is an OTC bentonite-based nasal spray gel marketed for the prevention and treatment… Read more . . .
-
Cessatech and pediatric medicines specialist Proveca have announced a deal that gives Proveca global commercialization rights to Cessatech’s CT001 sufentanil / ketamine analgesic nasal spray. Earlier this year, Cessatech initiated a Phase 3 trial of… Read more . . .
-
According to Liquidia Corporation, the FDA has granted tentative approval of the company’s sNDA for Yutrepia dry powder treprostinil for inhalation powder to add pulmonary hypertension associated with interstitial lung disease (PH-ILD) as an indication.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland